Selecta Biosciences, Inc. (SELB)
| Market Cap | 278.79M |
| Revenue (ttm) | 67.09M |
| Net Income (ttm) | -53.37M |
| Shares Out | 116.65M |
| EPS (ttm) | -0.48 |
| PE Ratio | n/a |
| Forward PE | 69.93 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,157,389 |
| Open | 2.46 |
| Previous Close | 2.50 |
| Day's Range | 2.37 - 2.52 |
| 52-Week Range | 2.37 - 5.70 |
| Beta | 1.04 |
| Analysts | Strong Buy |
| Price Target | 8.83 (+269.5%) |
| Earnings Date | n/a |
About SELB
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropat...
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for SELB stock is "Strong Buy." The 12-month stock price forecast is 8.83, which is an increase of 269.46% from the latest price.
News
Selecta Biosciences and Ginkgo Bioworks Announce New Collaboration to Develop Next-Generation Gene Therapy Capsids
WATERTOWN, Mass. and BOSTON, Jan. 10, 2022 /PRNewswire/ -- Selecta Biosciences, Inc. (Nasdaq: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic ...
Selecta Biosciences to Participate at the 2022 H.C. Wainwright BioConnect Conference
WATERTOWN, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapie...
Selecta Biosciences to Participate at the LifeSci Partners 11th Annual Corporate Access Event
WATERTOWN, Mass., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapie...
4 Penny Stocks Analysts Say To Buy Now & Targets Up To 117%
4 penny stocks with bullish price targets & buy ratings from analysts. The post 4 Penny Stocks Analysts Say To Buy Now & Targets Up To 117% appeared first on Penny Stocks to Buy, Picks, News and Informa...
Best Penny Stocks To Buy? 5 Short Squeeze Stocks To Watch Right Now
5 penny stocks with high short interest to add to your watch list in December. The post Best Penny Stocks To Buy?
10 Penny Stocks To Buy In December According To Insiders
Corporate insiders buy penny stocks & these 10 are getting purchased in December 2021. The post 10 Penny Stocks To Buy In December According To Insiders appeared first on Penny Stocks to Buy, Picks, New...
Sobi and Selecta Biosciences announce completion of enrolment in DISSOLVE Phase 3 study evaluating SEL-212 for chroni...
STOCKHOLM, Dec. 1, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced the completion of enrolment for DISSOLVE I, t...
Selecta Biosciences and Sobi Announce Completion of Enrollment in DISSOLVE Phase 3 Study Evaluating SEL-212 for Chron...
-DISSOLVE program on track with 12-month study fully enrolled- -DISSOLVE II on track for full enrollment in early 2022- -Top-line data from Phase 3 DISSOLVE program expected in H2 2022-
Selecta (SELB) Down on FDA's Clinical Hold on Phase I/II Study
The FDA issues a clinical hold on Selecta's (SELB) phase I/II study evaluating SEL-302 for the treatment of patients with methylmalonic acidemia. Shares down in after-hours trading.
Selecta Biosciences Provides Update on Phase 1/2 Clinical Trial of SEL-302 for the Treatment of Methylmalonic Acidemia
-U.S. FDA has issued a clinical hold on Phase 1/2 Clinical Trial of SEL-302 due to CMC related questions- -U.S. FDA has issued a clinical hold on Phase 1/2 Clinical Trial of SEL-302 due to CMC related q...
Selecta Biosciences to Participate in Jefferies Virtual London Healthcare Conference
WATERTOWN, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapie...
Selecta Biosciences, Inc. (SELB) Reports Q3 Loss, Tops Revenue Estimates
Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -128.57% and 82.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the...
Selecta Biosciences Reports Third Quarter 2021 Financial Results and Provides Business Update
-Established four strategic collaborations to advance next generation therapeutics and maximize the potential of ImmTOR platform-
Selecta Biosciences Posts Encouraging Data For ImmTOR Platform
Selecta Biosciences Inc (NASDAQ: SELB) announced top-line results from the Phase 1 study evaluating the ImmTOR platform to mitigate the formation of neutralizing antibodies against an adeno-associated v...
Selecta Biosciences Announces Top Line Data from the Phase I SEL-399 AAV Empty Capsid Study, Highlighting Potential B...
- At day 30, of subjects in the 0.3mg/kg ImmTOR cohort, 100% showed NAb titers of ≤ 1:25, and 67% showed NAb titers of ≤ 1:5 -
Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide B...
WATERTOWN, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapie...
Selecta Biosciences, Inc. (SELB) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Selecta Biosciences, Inc. (SELB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Selecta Biosciences, Ginkgo Bioworks Join Forces To Develop Rare Disease Treatments
Selecta Biosciences Inc (NASDAQ: SELB) and Ginkgo Bioworks Holdings Inc (NYSE: DNA) have collaborated to design novel and improved therapeutic potential enzymes for orphan and rare diseases. The partne...
Selecta Biosciences and Ginkgo Bioworks Announce Partnership to Advance Treatments for Orphan and Rare Diseases
BOSTON and WATERTOWN, Mass., Oct. 26, 2021 /PRNewswire/ -- Selecta Biosciences, Inc. (Nasdaq: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic t...
Selecta Biosciences and Genovis Enter Exclusive License Agreement to Advance Next-Generation IgG Protease in Gene The...
- Selecta obtains from Genovis exclusive worldwide rights to Xork, a differentiated IgG protease -
Selecta Biosciences to Participate in Jefferies Virtual Gene Therapy/Editing Summit
WATERTOWN, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapie...
Selecta Biosciences to Present New Data for the ImmTOR™ platform at the ESGCT 28th Annual Congress
WATERTOWN, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapie...
5 Top Penny Stocks Analysts Say To Buy Now With 123%-733% Targets
Will these penny stocks meet analysts' expectations? The post 5 Top Penny Stocks Analysts Say To Buy Now With 123%-733% Targets appeared first on Penny Stocks to Buy, Picks, News and Information | Penny...
Selecta Biosciences Announces Strategic Licensing Agreement with Takeda to Develop Next-Generation Gene Therapies for...
Selecta's ImmTOR™ platform enhances transgene expression and addresses adeno-associated virus (AAV) vector immunogenicity constraints to deliver transformative therapies Selecta's ImmTOR™ platform enhan...
Selecta Biosciences to Participate in Cantor Virtual Global Healthcare Conference
WATERTOWN, Mass., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapi...